On Tuesday, Akebia Therapeutics Inc (NASDAQ: AKBA) was -2.94% drop from the session before settling in for the closing price of $2.04. A 52-week range for AKBA has been $0.80 – $2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 5.16% over the past five years. When this article was written, the company’s average yearly earnings per share was at -1.19%. With a float of $207.21 million, this company’s outstanding shares have now reached $211.54 million.
Let’s look at the performance matrix of the company that is accounted for 167 employees. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akebia Therapeutics Inc stocks. The insider ownership of Akebia Therapeutics Inc is 5.03%, while institutional ownership is 24.85%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.19% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
You can see what Akebia Therapeutics Inc (AKBA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 1.63 million, a negative change from its year-to-date volume of 3.04 million. As of the previous 9 days, the stock’s Stochastic %D was 38.49%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 82.73%, which indicates a significant increase from 54.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.42% in the past 14 days, which was lower than the 63.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.70, while its 200-day Moving Average is $1.44. Nevertheless, the first resistance level for the watch stands at $2.03 in the near term. At $2.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.11. If the price goes on to break the first support level at $1.95, it is likely to go to the next support level at $1.92. Assuming the price breaks the second support level, the third support level stands at $1.87.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are 218,181K outstanding shares of the company, which has a market capitalization of 432.00 million. As of now, sales total 194,620 K while income totals -51,930 K. Its latest quarter income was 37,430 K while its last quarter net income were -20,040 K.
